OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-21.81%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$222M
AUM Growth
+$222M
(-31%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-9.76%
Top 10 Holdings %
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9
Top Buys
| 1 |
TELA Bio
TELA
|
$8.18M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$6.7M |
| 3 |
CUTR
Cutera, Inc.
CUTR
|
$5.54M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$1.94M |
Top Sells
| 1 |
CMRX
Chimerix, Inc.
CMRX
|
$9.3M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.68M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$6.78M |
| 4 |
Protagonist Therapeutics
PTGX
|
$5.96M |
| 5 |
Cytokinetics
CYTK
|
$4.09M |
Sector Composition
| 1 | Healthcare | 99.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Semler Scientific
SMLR
$429M
| – | – |
-70,000
| Closed | -$3.47M |
|
52
Repare Therapeutics
RPTX
$73.9M
| – | – |
-55,678
| Closed | -$793K |
|
|
53
Protagonist Therapeutics
PTGX
$3.62B
| – | – |
-251,500
| Closed | -$5.96M |
|
|
NCNA
54
NuCana
NCNA
$5.8M
| – | – |
-878,700
| Closed | -$878K |
|
55
Fulcrum Therapeutics
FULC
$353M
| – | – |
-136,000
| Closed | -$3.22M |
|
|
BCYC
56
Bicycle Therapeutics
BCYC
$492M
| – | – |
-175,000
| Closed | -$7.68M |
|